



Company	Starpharma Holdings Limited
Code	SPL
Meeting	AGM
Date	21 November 2019
Venue	RACV City Club, 501 Bourke Street, Melbourne
Monitor	Donald Pitkethly (proxy collector)

Number attendees at meeting	Approximately 55
Number of holdings represented by ASA	15
Value of proxies	\$432,000
Number of shares represented by ASA	330,000
Market capitalisation	\$491m
Were proxies voted?	Yes, on a poll
Pre AGM Meeting?	No

“VivaGel BV now on-market in UK, Europe and Australia; 100,000 units shipped

Great progress for the year with VivaGel BV and the VivaGel condom on the market and three other DEP products in clinical trials.

Starpharma do the R&D, use large pharmaceutical companies to do the marketing and distribution and 3rd party companies to do the manufacturing

Though the company had a loss for the year of \$14.3m, they still had \$41.3m cash at the end of the financial year. This was \$36.8m at the 30 September.

Compared to the 2018 AGM where there were many questions from concerned shareholders, this year’s meeting went very smoothly with no questions on the resolutions and no general questions until the Chair pleaded with the audience for a question and then there was one question on the cause of the delay in the US FDA approval for VivaGel BV. The CEO Dr Fairley said that it was common for new compounds to have approval delayed. The Chair said that he was “confident of success” for FDA approval of VivaGel BV.

The resolutions were passed with greater than 90% of votes FOR each of the three motions. All open ASA proxies were voted for the motions.

A recording of the proceedings is accessible from the Starpharma website along with the Chair's address and the CEO's slides from her presentation. There is plenty of detail on the slides and even a layperson can get a good understanding of the Company's products and plans.

No mention was made of future dividends although the Chair did state that the company was "well positioned to deliver returns to shareholders".

There have been many announcements during the past year. It is worth registering your email address on the Starpharma website if you wish to keep abreast of the advances.

The Chair expects that the "next three years should prove to be very exciting for shareholders". I am sure that investors will be hoping that it will be. All shareholders that I spoke to after the meeting said that they planned to hold onto their shares.